REGO reduces PI3K/AKT expression in colorectal, lung, breast, kidney and brain cancer cells both in vivo and in vitro, and in combination with the PI3K inhibitor PX-866 in a greater-than-additive manner to synergistically kill tumor cells [41]. Here, AKT1 is linked to neoplasm.